narvikk/E+ via Getty Images
Against a backdrop of rising geopolitical tensions between the US and China, there are signs of growing deal-making activity between Western pharmaceutical companies and Chinese biotech companies, a number of research firms suggest.
Large pharmaceutical companies have licensed almost a third of their external molecules from China
